Stock ABCL ABCELLERA BIOLOGICS INC.
Add to a list
To use this feature you must be a member
Log inSign up

Ratings AbCellera Biologics Inc.

Equities

ABCL

CA00288U1066

Market Closed - Nasdaq
Other stock markets
 01:30:00 03/05/2024 am IST 		5-day change 1st Jan Change
3.85 USD +1.85% Intraday chart for AbCellera Biologics Inc. +6.06% -32.57%
01/05 AbCellera Biologics Inc., Viking Global Investors, and ArrowMark Partners Collaborate to Launch New Biotech Companies CI
11/03 AbCellera, Biogen Collaborate to Discover Treatments for Neurological Diseases MT

Summary

  • On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.

Strengths

  • According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
  • Analysts covering this company mostly recommend stock overweighting or purchase.
  • The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
  • The opinion of analysts covering the stock has improved over the past four months.

Weaknesses

  • The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
  • The company has insufficient levels of profitability.
  • One of the major weak points of the company is its financial situation.
  • Based on current prices, the company has particularly high valuation levels.
  • For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
  • The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
  • Over the past four months, analysts' average price target has been revised downwards significantly.
  • Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
  • The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
  • The group usually releases earnings worse than estimated.

Ratings chart - Surperformance

Sector: Biotechnology & Medical Research

1st Jan change Capi. Investor Rating ESG Refinitiv
ABCELLERA BIOLOGICS INC. Stock AbCellera Biologics Inc.
-32.57% 1.11B -
MODERNA, INC. Stock Moderna, Inc.
+26.28% 42.68B
B-
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-3.99% 42.4B
B
LONZA GROUP AG Stock Lonza Group AG
+45.32% 40.04B
A
CELLTRION, INC. Stock Celltrion, Inc.
-6.20% 28.31B
C
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+6.36% 24.94B
B-
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-21.47% 18.96B
B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+27.58% 12.3B
C+
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-2.75% 11.95B
C+
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
-2.02% 11.55B
B+
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
-
EV / Sales
Price to Book
-
Price to Free Cash Flow
-
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. ABCL Stock
  4. Ratings AbCellera Biologics Inc.